Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29636024 | 1.00 | KDM1A (0.33) | KDM1AKCNH2KDM1BALDH1A1ACHE | |
| SCHEMBL7668174 | 0.84 | — | — | |
| SCHEMBL2329832 | 0.81 | ALDH1A1 (0.32) | ALDH1A1ACHE | |
| SCHEMBL29449513 | 0.81 | ALDH1A1 (0.32) | ALDH1A1ACHE | |
| SCHEMBL8761113 | 0.79 | ALDH1A1 (0.31) | ALDH1A1ACHE | |
| SCHEMBL5735519 | 0.79 | ALDH1A1 (0.36) | KDM1AKCNH2KDM1BALDH1A1ACHE | |
| SCHEMBL112218 | 0.79 | HDAC4 (0.36) | ALDH1A1ACHE | |
| SCHEMBL29918982 | 0.79 | HDAC4 (0.36) | ALDH1A1ACHE | |
| SCHEMBL172114 | 0.77 | ACHE (0.36) | ACHE | |
| SCHEMBL16550079 | 0.75 | CA1 (0.32) | KDM1AKCNH2KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1514864-B1 | Difluoralkyl aromatic compounds | SALTIGO GMBH (DE) | 2008-03-19 | — | — | EP | claimed |
| EP-1514864-A2 | Difluoralkyl aromatic compounds | Bayer Chemicals AG (DE) | 2005-03-16 | — | — | EP | claimed |
| US-20050054733-A1 | Difluoroalkylaromatics | LANXESS DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | claimed |
| US-12637461-B2 | Compounds for the activation of AMPK | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20240182468-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PFIZER (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024084390-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PFIZER INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240092781-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-21 | — | — | US | disclosed |
| US-11912822-B2 | Process of manufacturing polyols | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
| US-6348624-B1 | TREATING 1-BROMO-2,4-DIFLUOROBENZENE WITH STRONG, NON-NUCLEOPHILIC BASE, REACTING WITH ELECTROPHILIC REAGENT, TREATING WITH ALKALI OR ALKALINE EARTH METAL OR ORGANOMETALLIC REAGENT AND CARBON DIOXIDE, OR FORMYLATING AND OXIDIZING | THE PROCTER & GAMBLE CO. | 2002-02-19 | — | — | US | disclosed |
| US-6329391-B1 | ANTIBIOTICS, BACTERICIDES USING QUINOLONES | THE PROCTER & GAMBLE CO. | 2001-12-11 | — | — | US | disclosed |
| EP-1045823-A1 | PROCESS FOR MAKING CERTAIN BENZOIC ACID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-1015445-A1 | ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0963371-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1999035117-A1 | PROCESS FOR MAKING CERTAIN BENZOIC ACID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999014214-A1 | ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 1999-03-25 | — | — | WO | disclosed |
| WO-1998037072-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182468-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PRKAG1, PRKAG2, PRKAB1 | KDM1A 2934/4885KCNH2 3423/4885KDM1B 3232/4885 |
| US-20240092781-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | KDM1A 1017/4885KCNH2 781/4885KDM1B 1184/4885 |
| US-11912822-B2 | Process of manufacturing polyols | MRPL21, RER1, PCBP1 | KDM1A 385/4885KCNH2 959/4885KDM1B 481/4885 |
| US-12637461-B2 | Compounds for the activation of AMPK | PRKAG1, PRKAB1, PRKAA1 | KDM1A 3028/4885KCNH2 800/4885KDM1B 3328/4885 |
| US-20050054733-A1 | Difluoroalkylaromatics | NQO1, TYR, FLI1 | KDM1A 1712/4885KCNH2 2012/4885KDM1B 2170/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | KDM1A 1875/4885KCNH2 2393/4885KDM1B 1586/4885 |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | KDM1A 2268/4885KCNH2 447/4885KDM1B 2056/4885 |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | KDM1A 2170/4885KCNH2 1834/4885KDM1B 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.